title: Substance P receptor blockade decreases stretch-induced lung cytokines and lung injury in rats.
abstract: Overdistension of lung tissue during mechanical ventilation causes cytokine release, which may be facilitated by the autonomic nervous system. We used mechanical ventilation to cause lung injury in rats, and studied how cervical section of the vagus nerve, or substance P (SP) antagonism, affected the injury. The effects of 40 or 25 cmH(2)O high airway pressure injurious ventilation (HV(40) and HV(25)) were studied and compared with low airway pressure ventilation (LV) and spontaneous breathing (controls). Lung mechanics, lung weight, gas exchange, lung myeloperoxidase activity, lung concentrations of interleukin (IL)-1 beta and IL-6, and amounts of lung SP were measured. Control rats were intact, others were bivagotomized, and in some animals we administered the neurokinin-1 (NK-1) receptor blocking agent SR140333. We first determined the durations of HV(40) and HV(25) that induced the same levels of lung injury and increased lung contents of IL-1 beta and IL-6. They were 90 min and 120 min, respectively. Both HV(40) and HV(25) increased lung SP, IL-1 beta and IL-6 levels, these effects being markedly reduced by NK-1 receptor blockade. Bivagotomy reduced to a lesser extent the HV(40)- and HV(25)-induced increases in SP but significantly reduced cytokine production. Neither vagotomy nor NK-1 receptor blockade prevented HV(40)-induced lung injury but, in the HV(25) group, they made it possible to maintain lung injury indices close to those measured in the LV group. This study suggests that both neuronal and extra-neuronal SP might be involved in ventilator-induced lung inflammation and injury. NK-1 receptor blockade could be a pharmacological tool to minimize some adverse effects of mechanical ventilation.
authors.affiliation: UMR MD2 P2COE, Institut Fédératif de Recherche Jean-Roche, Université de la Méditerranée Aix-Marseille II, Marseille, France. fabienne.bregeon@ap-hm.fr
authors.forename: Fabienne
authors.initials: F
authors.lastname: Brégeon
authors.forename: Jean Guillaume
authors.initials: JG
authors.lastname: Steinberg
authors.forename: Nicolas
authors.initials: N
authors.lastname: Andreotti
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Sabatier
authors.forename: Stéphane
authors.initials: S
authors.lastname: Delpierre
authors.forename: Sylvie
authors.initials: S
authors.lastname: Ravailhe
authors.forename: Yves
authors.initials: Y
authors.lastname: Jammes
mesh_terms: D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008168:Lung / Q000378:metabolism*; D055370:Lung Injury / Q000378:metabolism / Q000517:prevention & control*; D023421:Models, Animal; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000494:pharmacology; D011812:Quinuclidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000187:drug effects / Q000378:metabolism; D012121:Respiration, Artificial / Q000009:adverse effects; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology
chemical_list: D016207:Cytokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; C085215:SR 140333